Published on 29 May 2024 on Zacks via Yahoo Finance
AstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca AZN reported overall survival (OS) data from a late-stage study, which evaluated its partner Daiichi Sankyo’s investigational candidate, datopotamab deruxtecan (Dato-DXd), compared with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Docetaxel is the current standard-of-care chemotherapy for this patient population.
Though the OS results numerically favored Dato-DXd, it failed to achieve statistical significance in the overall population of the phase III TROPION-Lung01 study. Shares of AstraZeneca declined 2.4% on May 28 in response to the news.